B+L to Present 14 Scientific Posters at ASCRS Annual Meeting
Bausch + Lomb announced the presentation of 14 scientific posters involving the company’s ophthalmic surgical technologies at the American Society of Cataract and Refractive Surgery annual meeting, July 23-27 in Las Vegas. The presentations include information on the company’s intraocular lens platforms and the cloud-based eyeTELLIGENCE software. View the schedule of presentations.
J&J Vision to Present Data on Latest Cataract Innovations at ASCRS Annual Meeting
Johnson & Johnson Vision announced that 21 company-sponsored studies supporting cataract surgery outcomes will be presented at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting. A complete listing of abstracts related to Johnson & Johnson Vision can be found on the ASCRS website. Read more.
Allergan to Present Data from Eye-care Portfolio at ASCRS Annual Meeting
Allergan will present new data from its portfolio of eye care medicines at the American Society for Cataract and Refractive Surgery Annual Meeting. Presentations will include new data on AGN-190584 (pilocarpine 1.25%), an investigational presbyopia treatment, and updated analyses on Durysta (bimatoprost intracameral implant). View the schedule of presentations.
Alcon to Present 70 Abstracts at ASCRS Annual Meeting
Alcon announced it would have approximately 70 abstracts highlighting the benefits of the Alcon cataract and refractive suite at the American Society for Cataract and Refractive Surgery Annual Meeting. The presentations include data on PanOptix and Vivity IOLs, the ARGOS Biometer with Image Guidance and the NGENUITY 3D Visualization System Heads-Up Display. View the ASCRS website for a list of presentations.
Allegro Ophthalmics to Present Results of ALG-1007 Ex-U.S. Phase II Trial at ASCRS Annual Meeting
Allegro Ophthalmics announced the results of the company’s second ALG-1007 ex-U.S. clinical trial for the treatment of dry-eye disease will be presented during the ASCRS/ASOA meeting. On July 24, Eric D. Donnenfeld, MD, will present full study results of the company’s second ALG-1007 ex-U.S. clinical trial for DED. View the schedule of presentations.
More OpRegen Data in Patients with Dry AMD with GA Released
Lineage Cell Therapeutics reported updated interim results from its ongoing, 24-patient Phase I/IIa clinical study of its lead product candidate, OpRegen. OpRegen is an investigational cell therapy consisting of allogeneic retinal pigment epithelium cells, administered one time to the subretinal space, for the treatment of dry age-related macular degeneration with geographic atrophy. These updated results include a minimum of six months of follow-up in all 24 patients treated with OpRegen, including all 12 patients treated in cohort 4, which had better baseline vision and smaller areas of GA at baseline than earlier cohorts. Read more.
Nanoscope Announces First Patient Dosed in Phase IIb Trial
Nanoscope Therapeutics announced the first patient was dosed in its Phase IIb clinical trial of MCO-010, an ambient-light activatable optogenetic monotherapy to restore vision in patients with retinitis pigmentosa. Based on preliminary evidence from the company's Phase I/IIa study, MCO-010 has received FDA orphan drug designations for RP and Stargardt’s disease. Read more.
Harrow Health Granted Two Patents for Novel Surgical Dilation Formulation
Harrow Health announced the U.S. Patent and Trademark Office issued two Patents titled “Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof.” Read more.
NovaBay Partners with ImprimisRx to Promote Prescription Avenova
NovaBay Pharmaceuticals is partnering with ImprimisRx, a wholly owned subsidiary of Harrow Health, to promote prescription lid and lash cleanser Avenova. Read more.
Lensar Announces Presentations at ASCRS Annual Meeting
Lensar announced 12 abstracts highlighting Lensar’s technology were accepted for presentation at ASCRS. In addition, the company will host in-person demonstrations of its ALLY Adaptive Cataract Treatment System, which combines the femtosecond laser with phaco technology. Lensar expects to submit a 510(k) application for regulatory clearance of ALLY in the first quarter of 2022. View the list of presentations.
Nanodropper & Unite For Sight Announce Global Health Partnership
Nanodropper is joining forces with Unite For Sight to launch a global health initiative aimed at providing better access to vision-saving medications in Ghana. The initiative will allow the public to donate Nanodroppers to Unite For Sight partner clinics in Ghana at $9 per adaptor, a substantially lower price than retail value. The company says the Nanodropper reduces the waste from a typical eyedrop. Learn more.
Euclid Systems Appoints Dr. Thompson as Chief Medical Officer
Euclid Systems appointed Vance Thompson, MD, an internationally recognized authority in laser vision correction and advanced cataract surgery, to the position of chief medical officer. Read more.